A study which tracked almost 10,000 women with BRCA1 or BRCA2 gene mutations for up to 20 years has provided the clearest picture yet of the long-term breast and ovarian cancer risks for women who have inherited an abnormality in these cancer-risk genes.
Research led by Peter Mac has found a way to map, in unprecedented detail, all of a drug’s clinically important interactions in the body. The new tools can reveal how a small-molecule drug works at the cellular or genetic level, providing scientists with powerful new insights into what drives or - importantly - limits its anti-cancer effect.
Australian researchers have found a new way to use immunotherapy, a breakthrough mode of cancer treatment which harnesses the patient’s immune system, to treat an aggressive form of breast cancer. The researchers at Peter MacCallum Cancer Centre and Walter and Eliza Hall Institute have shown, for the first time, that combining two immunotherapy drugs could be effective in treating triple negative breast cancers arising in women with BRCA1 mutations.
An Australian-led trial has shown a new drug works in almost five times as many patients, and has more durable benefits, compared to standard therapy for a rare skin-related cancer. The multi-centre Phase 3 clinical trial involved patients with cutaneous T-cell lymphoma, a cancer which causes debilitating and worsening skin problems and for which there is no known cure.
The Women’s, the Royal Melbourne and the Peter MacCallum Cancer Centre held a combined event today to acknowledge National Sorry Day and affirm our joint commitment to righting the wrongs of the past and continuing along the journey of reconciliation.
Clinical trials give our researchers and clinicians crucial evidence about the effect of new or experimental cancer treatments to guide our advances in cancer care. For patients like John Mailes, diagnosed in 2001 with a rare cancer which at that time had no effective treatment, a clinical trial can also deliver a new lease on life.
Peter Mac and Monash Health are working together as part of an international trial to provide single-dose radiation therapy to woman at the same time they undergo surgery for breast cancer. The trial of intra-operative radiation therapy (IORT) allows women to receive their required radiation dose in less than ten minutes, in a procedure that occurs during surgery to remove their tumour.
Peter Mac's Professor Mark Dawson has been selected as a Howard Hughes Medical Institute (HHMI) International Research Scholar. The scholarship recognises Prof Dawson as a leading early-career scientist working outside of the G7 group of countries.
12,000+ Australians diagnosed with blood cancers each year could soon have access to a simple blood test to monitor their disease thanks to a world-first ‘liquid biopsy’ developed at Peter MacCallum Cancer Centre.
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.